An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
AtriCure, Inc. (NASDAQ: ATRC), a leader in surgical treatments for atrial fibrillation (Afib), announced its first quarter 2023 financial results will be released on May 2, 2023. The company will host an audio webcast at 4:30 p.m. Eastern Time on the same day to discuss these results. Interested participants can register here. AtriCure focuses on innovative technologies for Afib treatment, with products like the Isolator® Synergy™ Ablation System and AtriClip® Left Atrial Appendage Exclusion System, addressing a condition affecting over 37 million people worldwide.
Positive
AtriCure's upcoming release of Q1 2023 financial results may provide insights into company performance.
The company continues to lead in innovative technologies for Afib, highlighting significant market presence.
Negative
No specific financial metrics or guidance provided for Q1 2023, potentially leaving investors uncertain.
MASON, Ohio--(BUSINESS WIRE)--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release first quarter 2023 financial results on Tuesday, May 2, 2023.
AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, May 2, 2023, to discuss its first quarter 2023 financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the audio webcast will be available at https://ir.atricure.com/events-and-presentations/events.
About AtriCure
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.
